Booster vaccines do not protect recovered Covid-19 patients

Source: (https://bit.ly/3BqxFeS)
Measuring the effectiveness of the Moderna and Pfizer boosters
against the BA.1 Omicron subvariant, researchers found that
a booster upped protection against infection by just 6.1 percent
for those who had a documented prior infection, or natural
immunity.
The effectiveness of a primary series 14 to 149 days after a second
dose was pegged as 41 percent for the group. A booster brought
the protection to 47.1 percent.
Excluding people with a documented prior infection, the booster
increased infection more.
People without documentation of a COVID-19 infection had 27.1
percent protection after a primary series. A booster increased that
to 54.1 percent.
"While booster vaccination was associated with additional protection
against Omicron BA.1 infection in people without a documented
prior infection, it was not found to be associated with additional
protection among people with a documented prior infection,"
researchers said.
U.S. researchers including Dr. Margaret Lind, an epidemiologist
at the Yale School of Public Health, performed the research. They
analyzed COVID-19 tests that were entered into the Yale New Haven
Health system between Nov. 1, 2021, and April 30, 2020. They
compared 11,307 COVID-19 cases, including 672 cases among people
who had a documented prior case, to 130,041 controls, including
10,473 with documentation of a prior case.
Pfizer and Moderna did not respond to requests for comment.
The boosters administered during the time period studied have since
been replaced by updated versions.
A number of studies have analyzed the protection people enjoy after
recovering from COVID-19 and found that the protection is higher
than that conferred by vaccines. Both forms of protection have waned
against infection and to a smaller degree against severe illness, but
natural immunity has held up better against both infection and severe
disease.
More recent studies have found that people sickened with strains
before Omicron emerged in late 2021 have less protection against
Omicron and its subvariants, but that prior Omicron infection
generally protects well against reinfection. For severe disease,
any infection serves as strong shielding.
Many people around the world have had at least one COVID-19
infection, according to seropositivity surveys.
COVID-19 cases first began appearing in 2019.
Some scientists promote so-called hybrid immunity, or vaccination
despite prior infection. One recent paper found that people with
infections prior to Omicron had 44 percent and 81 percent,
respectively, protection against infection and hospitalization but
that the protection was higher among those with one, two, or three
doses of a vaccine.
The new study identified poor effectiveness from both a primary
series and a booster against infection, particularly among the
naturally immune.
Unadjusted effectiveness for a primary series among people without
a prior infection was just 13.5 percent less than 14 days after
a second dose and negative 28.8 percent 14 to 149 days after the
final shot of the primary series. At or more than 150 days following
a second dose, the effectiveness was estimated at 5.8 percent.
For people with a prior infection, the figures were 1.3 percent,
5 percent, and 9.2 percent.
Adjusted effectiveness, of effectiveness after correcting for factors
such as age, determined the effectiveness among the non-naturally
immune group peaked at just 27.1 percent and dropped to 13.6
percent. A booster at and after 14 days increased that to 54.1
percent, but boosters quickly wane, other research has shown.
Among those with a documented prior infection, and after
adjustments, effectiveness peaked at 41 percent and dropped
to 32.1 percent. A booster increased effectiveness to 47.1 percent.
The study is the latest to show that a primary series - two shots
 - of one of the messenger RNA vaccines - both the Pfizer and
Moderna vaccines - provides little protection against infection and
severe illness.